This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck KGaA

Drug Names(s): EMD 121974

Description: Cilengitide is a cyclic arginine-glycine-aspartic acid peptide that targets avß3 integrin, expressed on neovasculature. It may stop the growth of cancer cells by preventing the tumor from growing its own blood vessels, thus supressing the growth and spread of tumor cells.

Deal Structure: MDxHealth (formerly OncoMethylome) and Merck KGaA
In June 2008, OncoMethylome Sciences announced that it has signed a licensing and testing agreement with Merck KGaA. Under the terms of the agreement, OncoMethylome will provide MGMT gene promoter methylation testing services for Merck's clinical trial program of cilengitide. As part of the agreement, Merck received a worldwide, non-exclusive license from OncoMethylome to use the results of the OncoMethylome MGMT gene promoter methylation assay for optimizing glioblastoma multiforme (GBM) treatment with cilengitide. Financial terms of the agreement are not disclosed.

In June 2011, MDxHealth announced that it will extend its agreement with Merck KGaA for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials. Financial terms of the agreement are not disclosed.

In July 2012, MDxHealth announced that it has expanded its collaboration with Merck KGaA. This expanded collaboration covers the...See full deal structure in Biomedtracker

Cilengitide News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug